Another company has recalled a drug that was made at the Novartis plant east of Lincoln.
GlaxoSmithKline last week announced it was recalling 394,230 bottles of the blood pressure drug DynaCirc CR.
Novartis manufactured the generic drug on a contract basis at the Lincoln site.
GlaxoSmithKline said in a statement it had received no complaints of any contamination or tablet mixups, but a Food and Drug Administration enforcement report dated Feb. 22 said the medicines were being recalled "due to compliance concerns regarding the level of (good manufacturing) compliance and procedural controls related to line clearance during the packaging process at the Novartis Consumer Health site."
The GlaxoSmithKline action is the second recall of drugs made at the site since the beginning of the year.
Novartis recalled several of its over-the-counter medicines Jan. 8, including Excedrin, Bufferin, GasX and NoDoz.
The next day, the FDA sent out a warning, saying pain medications Novartis manufactured in Lincoln for Endo Pharmaceuticals could have been contaminated with other products.
The FDA, however, stopped short of ordering the drugs recalled.
Novartis shut down manufacturing at the Lincoln plant in mid-December after back-to-back scathing inspection reports from the FDA.
The FDA documented numerous repeat violations, including the failure to investigate numerous consumer complaints and poor quality-control procedures that allowed some medicines produced there to become contaminated.
The shutdown already has cost Novartis more than $200 million, and the company has said it does not expect the plant to restart production until the summer.
Despite laying off more than 100 temporary workers, the company has kept all of the more than 600 permanent employees working during the shutdown.